Not a good buy right now for an impatient entry: price just jumped on strong Q3/news, but momentum indicators are still weak and price is below the key pivot (overhead resistance).
Near-term stats based on similar candlestick patterns lean bearish (expected drift lower over 1 week to 1 month), so chasing here has a poor risk/reward.
If already owned, fundamentals/news are strong enough to justify holding; for a new position, the setup is not attractive today.
Technical Analysis
Trend/Momentum: MACD histogram is negative (-1.951) and only “negatively contracting” (improving, but still bearish) → momentum has not flipped to bullish yet.
RSI: RSI_6 = 41.4 (neutral-to-weak) → not oversold, not showing strong buy pressure.
Moving averages: converging MAs → consolidation/indecision after a move; not a clean uptrend signal.
Key levels:
Current ~141 is below Pivot 144.719 (acts like near-term resistance).
Support: S1 136.388 then S2 131.241.
Resistance: R1 153.051, R2 158.198.
Price action context: +3.6% regular-session pop suggests earnings/news was bought, but technicals imply follow-through is uncertain and a pullback toward support is plausible.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Positioning (OI): Put/Call OI ratio 0.66 (more calls than puts) → mildly bullish positioning.
Activity (Volume): options volume shows 0 today (no confirming flow) → sentiment signal from trading activity is weak.
Volatility: IV30 ~38% vs HV ~34% (IV slightly elevated); IV percentile ~50.6 (mid-range) → options are not screaming cheap/expensive, but not providing a clear edge.
Technical Summary
Sell
9
Buy
4
Positive Catalysts
results**: revenue and profit up YoY; non-GAAP EPS beat (per news).
Overall: fundamentals are clearly improving (growth + fundraising + AUM), but the stock’s near-term entry timing looks technically unfavorable today.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: ratings/targets have been moving upward (multiple target raises; several Buy/Outperform reiterations; one Equal Weight).
Notable updates:
Oppenheimer: Outperform, PT raised to $220 (from $190).
Keefe Bruyette: Outperform, PT raised to $170 (from $161).
Goldman Sachs: upgraded to Buy, PT $165.
UBS: initiated Buy, PT $166.
Morgan Stanley: Equal Weight, PT $159 (more cautious vs peers).
Wall Street pros: exposure to fast-growing alts segments (wealth/secondaries), durable growth profile, fundraising momentum.
Wall Street cons: at least one major shop remains neutral/equal-weight, implying valuation/near-term upside may be more balanced after moves.
Influential/political trading: no recent congress trading data available; no politician activity indicated in provided data.
Wall Street analysts forecast HLNE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HLNE is 166.67 USD with a low forecast of 154 USD and a high forecast of 181 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast HLNE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HLNE is 166.67 USD with a low forecast of 154 USD and a high forecast of 181 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
2 Hold
0 Sell
Moderate Buy
Current: 131.720
Low
154
Averages
166.67
High
181
Current: 131.720
Low
154
Averages
166.67
High
181
JPMorgan
Neutral
maintain
$164 -> $166
AI Analysis
2026-02-04
New
Reason
JPMorgan
Price Target
$164 -> $166
AI Analysis
2026-02-04
New
maintain
Neutral
Reason
JPMorgan raised the firm's price target on Hamilton Lane to $166 from $164 and keeps a Neutral rating on the shares. The firm updated the company's model post the earnings report.
Oppenheimer
Oppenheimer
Outperform
maintain
$220 -> $230
2026-02-04
New
Reason
Oppenheimer
Oppenheimer
Price Target
$220 -> $230
2026-02-04
New
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Hamilton Lane to $230 from $220 and keeps an Outperform rating on the shares. The firm notes Hamilton Lane had a strong Q3 and the stock initially opened up 3% before ultimately selling-off by market close as the Alts sector was further pressured by credit concerns that Oppenheimer views as misguided.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for HLNE
